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Evidence from clinical and experimental data suggests that thyrotropin receptor (TSHR) 
signaling is involved in energy expenditure through its impact on white adipose tissue 
(WAT) and brown adipose tissue (BAT). TSHR expression increases during mesenchymal 
stem cell (MSC) differentiation into fat. We hypothesize that TSHR activation [TSHR*, 
elevated thyroid-stimulating hormone, thyroid-stimulating antibodies (TSAB), or acti-
vating mutation] inuences MSC differentiation, which contributes to body composition 
changes seen in hypothyroidism or Graves’ disease (GD). The role of TSHR activation 
on adipogenesis was rst investigated using ex vivo samples. Neck fat (all euthyroid at 
surgery) was obtained from GD (n = 11, TSAB positive), toxic multinodular goiter (TMNG, 
TSAB negative) (n = 6), and control patients with benign euthyroid disease (n = 11, TSAB 
negative). The effect of TSHR activation was then analyzed using human primary abdom-
inal subcutaneous preadipocytes (n = 16). Cells were cultured in complete medium (CM) 
or adipogenic medium [ADM, containing thiazolidinedione (TZD), PPARγ agonist, which 
is able to induce BAT formation] with or without TSHR activation (gain-of-function mutant) 
for 3 weeks. Adipogenesis was evaluated using oil red O (ORO), counting adipogenic foci, 
qPCR measurement of terminal differentiation marker (LPL). BAT [PGC-1α, uncoupling 
protein 1 (UCP1), and ZIC1], pre-BAT (PRDM16), BRITE− (CITED1), or WAT (LEPTIN) 
markers were analyzed by semiquantitative PCR or qPCR. In ex vivo analysis, there were 
no differences in the expression of UCP1, PGC-1α, and ZIC1. BRITE marker CITED1
levels were highest in GD followed by TMNG and control (p for trend =  0.009). This 
was associated with higher WAT marker LEPTIN level in GD than the other two groups 
(p < 0.001). In primary cell culture, TSHR activation substantially enhanced adipogenesis 
with 1.4 ± 0.07 (ORO), 8.6 ± 1.8 (foci), and 5.5 ± 1.6 (LPL) fold increases compared with 
controls. Surprisingly, TSHR activation in CM also signicantly increased pre-BAT marker 
PRDM16; furthermore, TZD-ADM induced adipogenesis showed substantially increased 
BAT markers, PGC-1α and UCP1. Our study revealed that TSHR activation plays an 
important role in the adipogenesis process and BRITE/pre-BAT formation, which leads to 
WAT or BAT phenotype. It may contribute to weight loss as heat during hyperthyroidism 
and later transforms into WAT posttreatment of GD when patients gain excess weight.
Keywords: adipogenesis, thyrotropin receptor, body composition, white adipose tissue, BRITE adipocytes, brown 
adipose tissue
Abbreviations: TSHR, thyrotropin receptor; MSC, mesenchymal stem cell; TSAB, thyroid-stimulating antibodies; CM, com-
plete medium; ADM, adipogenic medium; WAT, white adipose tissue; BAT, brown adipose tissue.
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INTRODUCTION
Excess thyrotropin receptor (TSHR) activation occurs in two 
common conditions, Graves’ disease (GD) in which thyroid-
stimulating antibodies (TSAB) mimic thyroid-stimulating horm -
one (TSH) causing hyperthyroidism and primary hypothyroidism 
when elevated circulating TSH compensates for low thyroid 
hormone (T4/T3) levels resulting from the failing gland (1). Both 
confer alterations in body composition, e.g., more than 90% of 
people with GD lose weight, mainly muscle mass and fat (2), 
while hypothyroidism increases fat and bone mineral density. 
e opposing dierences of thyroid hormone levels have been 
traditionally suggested for these changes of body compositions, 
e.g., impact on white adipose tissue (WAT) or brown adipose 
tissue (BAT) metabolism (3, 4). BAT depots were thought to be 
absent from adult humans, but the availability of imaging using 
18F-uorodeoxyglucose positron emission tomography and com-
puted tomography reveals their location in supraclavicular and 
neck regions (5–7).
Despite restoration of serum TSH concentrations to normal, 
many GD patients complain of substantial weight gain post 
treatment (8, 9) with potential negative impact on their future 
cardiovascular risk. Further studies in this area may therefore 
have considerable impact on determining the optimal treatment 
for patients with GD. ere is still considerable controversy 
regarding the best treatment for Graves’ hyperthyroidism and 
radioiodine and/or thyroidectomy might be associated with more 
weight gain compared to those on antithyroid drugs and patients 
who undergo ablative therapy for thyroid cancer (10–12). is 
suggests that there are some factors associated with GD that 
inuence post therapy weight gain. Furthermore, analysis has 
suggested that a diagnosis of GD (as opposed to other causes of 
thyroid over-activity) is an independent predictor of weight gain 
(10), raising the possibility that the persisting anti-TSH recep-
tor antibodies in such patients might have long-term eects on 
peripheral adipose tissue composition (13). In humans, lipolysis 
was shown to be stimulated by TSH and TSAB, but this was 
conned to neonates suggesting an eect predominantly on BAT 
(14). Furthermore, the presence of functional extrathyroidal 
TSHR has been demonstrated in adipose tissue (15, 16) and 
bone (17), and fat-specic knockout of TSHR generated mice 
with larger adipocytes (18). More recent studies report a positive 
correlation between TSHR activation and obesity (19–21), and 
reports using animal models suggest a role for the TSHR in BAT 
and WAT function (22–24). For example, TSHR-decient hyt/hyt 
mice became hypothermic in cold conditions, despite thyroxine 
administration, but transfection of TSHR into BAT of these 
mice improved core temperature (22). e above evidence led 
us to hypothesize that TSHR activation per se may contribute to 
changes in body composition separately from the eects of thy-
roid hormone levels, exerting a direct impact on adipose tissues 
metabolism (25).
Brown adipose tissue dissipates energy as heat (thermogen-
esis) in a process mediated by uncoupling protein 1 (UCP1), 
which uncouples oxidative phosphorylation from ATP produc-
tion (26). WAT and BAT are derived from distinct lineages of 
mesenchymal stem cells (MSCs), Myf5+ for BAT (also muscle 
progenitors) but Myf5− for WAT (27). e two adipose types also 
dier morphologically with WAT having a single large fat vacuole 
and BAT having many smaller fat droplets and higher numbers of 
mitochondria (28). In addition to WAT and newly documented 
adult BAT (5), human beige (or BRITE for BRown in whITE) adi-
pocytes have been recently identied, and like WAT are derived 
from Myf5− MSC (29). Although there are clearly dened BAT, 
BRITE, and WAT depots in mice, human fat depots tend to 
be heterogeneous with BRITE/pre-BAT adipocytes present in 
both WAT and inducible BAT depots with the potential to be 
transformed to either WAT or BAT (30, 31). Transcription factor 
PRDM16 plays an essential role in the transformation of BRITE/
pre-BAT to BAT (32). Adipocytes are generated by lineage-
specic dierentiation of MSC found in fat (33); the expression of 
TSHR is increased in human fat depots undergoing adipogenesis 
(34). We hypothesize that TSHR activation could thus modulate 
fat formation. Our aim was to investigate the eect of TSHR 
activation on human adipose tissue from the neck, which is 
recognized as a BAT inducible region (5), by phenotyping ex vivo
samples using markers for WAT, BRITE, and BAT. Furthermore, 
we analyzed preadipocytes obtained from subcutaneous adipose 
tissue, to address the role of TSHR activation in adipogenesis and 
modulation of fat phenotype.
MATERIALS AND METHODS
All reagents were obtained from Sigma-Aldrich and tissue culture 
components from Cambrex unless otherwise stated.
Adipose Tissue Collection
Subcutaneous adipose tissue (n= 16) was collected from patients 
undergoing elective open abdominal surgery for non-metabolic 
conditions. For ex vivo analysis, subcutaneous neck fat samples 
were obtained from GD (n =  11), toxic multinodular goiter 
(TMNG) (n= 6) and euthyroid control patients with benign thy-
roid nodules (n = 11) undergoing thyroid surgery. Five patients 
have undetectable TSH measurements (GD = 4 and TMNG = 1) 
with normal free T4 (one at upper limit normal level) or T3 levels. 
e suppressed TSH is expected in treated hyperthyroid patients 
as this will take months to recover despite being euthyroid. 
It should be stressed that all patients were clinically euthyroid 
during surgical procedure and patients’ information has been 
summarized in Table 1. All GD patients have positive TSHR anti-
bodies measured by thyroid-binding inhibiting immunoglobulin 
assays and TSAB luciferase reporter assay (35).
Generation of TSHR*-Expressing Cells
Preadipocyte/broblasts were obtained by collagenase digest, 
as previously described (36). Cells were used at low passage 
number (<5); hence, not all samples were analyzed in all experi-
ments. Activating mutant TSHR (L629F) was introduced into 
the preadipocyte populations using retroviral vectors, previously 
produced in our laboratory (37). Geneticin selection resulted 
in mixed populations stably expressing the various TSHR, 
which exhibit increased basal levels of cAMP compared with 
the equivalent non-modied cell population, all as previously 
described (16).
TABLE 1 | Patients demographic.
Patient ID Sex Age Hist FT3 FT4 TSH TRAB TPO TSAB EUT (months)
GD
GD1 M 47 GD 13.0 2.06 32 2.6 8
GD2 F 71 GD 4.7 11.4 6.83 4.7 <2 2.9 7
GD3 F 23 GD 7.1 7.84 <1 1,059 3.0 7
GD4 M 48 GD 4.3 14.9 0.04 11.7 <2 2.4 4
GD5 F 63 GD 22.4 <0.02 6.7 2.5 3
GD6 F 39 GD 5.6 17.5 <0.02 3.1 6
GD7 F 52 GD 5.6 9.3 0.29 15.8 >1,000 3.0 21
GD8 F 38 GD 13.2 0.43 2.9 12
GD9 M 31 GD 12.3 2.34 3
GD10 F 57 TMNG 4.5 12.9 <0.02 19.3 648 2.7 10
GD11 F 27 TMNG 4.6 14.1 <0.02 3.3 6
Toxic MNG
MNG1 F 43 TMNG 5.3 17.8 <0.02 1.6 2
MNG2 M 76 TMNG 13.0 0.1 <1 1.1 9
MNG3 F 61 TMNG 14.3 0.92 50 1.2 20
MNG4 F 70 TA 13.0 1.22 <1 12.5 1.2 16
MNG5 M 61 TMNG 13.5 0.21 1.2 21
MNG6 M 89 TMNG 14.1 0.25 1.1 9
Control
CO1 F 21 CN 13.5 1.56 1.4
CO2 F 78 HN 13.0 3.26 1.1
CO3 F 46 BC 12.6 1.46 1.2
CO4 F 71 EMNG 16.7 1.79 1.3
CO5 M 50 EMNG 12.2 0.61 1.1
CO6 F 27 EMNG 14.0 2.58 <2 1.2
CO7 F 78 EMNG 13.7 0.11 1.8
CO8 F 27 EMNG 14.6 1.09 1.2
CO9 F 61 EMNG 14.0 0.57 <2 1.3
CO10 M 45 EMNG 16.5 0.83 <2 1.4
CO11 F 71 EMNG 13.0 0.65 300 1.2
F, female; M, male; Hist, histology; EUT, euthyroid duration; GD, Graves’ disease; TMNG, toxic multinodular goiter; EMNG, euthyroid multinodular goiter; TA, toxic adenoma; CN, 
colloid nodules; HN, hyperplastic nodules; BC, benign cyst.
Normal reference: FT3 (2.6–5.7 pmol/l), FT4 (9.2–22 pmol/l), thyroid-stimulating hormone (TSH) (0.30–4.40 mU/l), thyroid receptor antibodies (TRAB; <1 negative, 1–1.4, borderline 
>1.4 U/l positive), thyroid peroxidase antibodies (TPO) (<32 kU/l is negative), and thyroid-stimulating antibodies (TSAB; stimulation index 97.5th SD of normal <1.4 is negative).
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Preadipocyte/Fibroblast Culture In Vitro
Adipogenesis
Preadipocytes were cultured in DMEM/F12 10% FCS (complete 
medium, CM). Adipogenesis was induced in conuent cells by 
replacing with dierentiation medium [adipogenic medium 
(ADM)] containing 10% FCS, biotin (33μM), panthothenate 
(17μM), T3 (1nM), dexa-methasone (100nM), thiazolidinedione 
(TZD) (1μM), and insulin (500nM) for 22 days, adipogenesis was 
assessed by microscopic examination to detect the characteristic 
morphological changes (cell rounding, accumulation of lipid 
droplets), acquisition of lipid lled droplets [oil red O (ORO) 
staining], and transcript measurement of adipogenic markers 
(PPARγ, LPL) by qPCR as described previously (16). In addition, 
foci of dierentiation (groups of cells with lipid droplets) were 
counted in 10 dierent elds for each experimental condition (36).
PCR Analysis of Markers for WAT, BRITE, 
or BAT
Transcript copy numbers for various genes, including markers for 
WAT [LEPTIN (38)], BRITE [CITED1 (39)], pre-BAT (PRDM16), 
and BAT [PGC-1α, UCP1, and ZIC1 (30, 31)] together with TSHR
were measured.
Total RNA from cells or ex vivo fat tissues was extracted and 
reverse transcribed using standard protocols (16) for standard or 
qPCR analysis; primers (cross exon boundaries to avoid ampli-
cation of genomic DNA) were designed using primer 3 soware 
(Table S1 in Supplementary Material). qPCR was conducted 
using SYBR Green incorporation measured on a Stratagene 
MX 3000. Comparison with plasmid standard curves for each 
gene permitted calculation of absolute values for each sample 
(transcripts per microgram input RNA). In addition, for qPCR, 
transcripts of a housekeeping gene, APRT, were measured so 
that values could be expressed relative to this (transcripts/1,000 
APRT). APRT was also used in the comparative Ct method to 
assess transcript levels of PRDM16. It should be noted that none 
of the treatments used resulted in a variation in the APRT Ct 
value of more than one cycle. In qPCR experiments, all measure-
ments were made in triplicate; the standard curve was also run 
in at least duplicate.
If multiple products (e.g., primer dimer) were detected by 
qPCR (dissociation curve), a classic PCR with densitometry 
technique was used. Standard PCR was performed to detect 
CITED1 and LEPTIN using Phusion High-Fidelity PCR master 
mix (ermo Scientic) as per the manufacturer’s instructions. 
e PCR products were resolved on 2% agarose gels for 35 min, 
FIGURE 1 | Ex vivo analysis of deep neck fat. Samples were snap frozen, and total RNA was isolated. Gene transcripts were measured by qPCR, (A) thyrotropin 
receptor (TSHR); (B) ZIC1 (brown adipose tissue marker), shown as transcript copy number (TCN) per 1,000 copies of housekeeper gene APRT (adenosine 
phosphoribosyl transferase); standard PCR was used to analyze (C) LEPTIN (white adipose tissue marker), (D) CITED1 (BRITE marker), densitometry were 
measured and corrected to housekeeping gene (GAPDH). Representative photos were shown (gels with all samples had been included in Figure S1 in 
Supplementary Material). Post-ANOVA test for linear trend of CITED1 was performed (p = 0.009). Results expressed as mean ± SD of all samples studied  
(each performed in duplicate) (**p ≤ 0.01; ***p < 0.001).
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and densitometry values were obtained and corrected to house-
keeping gene (GAPDH).
Statistical Analysis
Parametric data were analyzed using Student’s t-test and one-way 
ANOVA for multiple group comparisons where appropriate. 
Similarly, Mann–Whitney U test and Kruskal–Wallis H test 
was used for non-parametric data. All analysis was done using 
two-tailed tests. Parametric data were presented as mean ± SD 
and median ± interquartile range for non-parametric data. In all 
cases, p < 0.05 was considered signicant.
RESULTS
TSHR Activation Favor BRITE and WAT 
Formation in Ex Vivo Analysis
To examine the role of TSHR activation on adipose tissues, we 
analyzed markers of WAT, BRITE, and BAT using ex vivo samples 
of subcutaneous neck fat. Analyzed samples were obtained when 
patients were euthyroid, but the persisting TSAB result in GD 
fat samples experiencing ongoing TSHR activation while TMNG 
and control samples do not.
Expression levels of TSHR did not dier in control, TMNG, 
or GD groups (Figure 1A); we then analyzed the potential eect 
of TSAB/TSHR* on fat phenotype. Higher transcript levels of 
LEPTIN (WAT marker) were detected in GD samples compared 
to TMNG and control (p < 0.001) (Figure 1C), which indicates 
that adipogenesis in the WAT compartment is ongoing in GD. BAT 
markers PGC-1α, UCP1, and ZIC1 were detected, even though 
there was no dierence in expression levels between the three 
groups (Figure  1B). However, a well-dened BRITE marker, 
CITED1, showed highest transcript levels in GD samples, fol-
lowed by TMNG and control (p value, test for trend = 0.0009) 
(Figure 1D).
ese data suggest that TSHR activation is associated with 
WAT and BRITE fat generation; subsequently, we tried to under-
stand the role of TSHR activation on adipogenesis using primary 
cell cultures.
TSHR Activation Enhances Subcutaneous 
Adipogenesis Induced In Vitro
We rst investigated the eects of TSHR signaling on adipo-
genesis using subcutaneous preadipocytes stably expressing 
or not activating mutant TSHR (L629F, TSHR*). TSHR activa-
tion did not induce spontaneous adipogenesis in subcutaneous 
FIGURE 2 | Adipogenesis in subcutaneous preadipocytes was 
assessed by foci counting (n = 11, representative photos were shown 
with arrows indicating differentiating adipocytes), LPL transcripts 
measured by qPCR (n = 9) and oil red O (ORO, n = 4). Result presented 
as fold increase in TSHR* populations relative to empty vector controls. The 
table reports raw data for qPCR results expressed as transcript copy number 
per 1,000 copies of housekeeper gene APRT (adenosine phosphoribosyl 
transferase), together with foci numbers and ORO optical density values 
(mean ± SEM). Histograms = mean ± SEM of all samples studied (each 
performed in duplicate) (*p < 0.05; **p ≤ 0.01; ***p < 0.005).
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precursors even when the cells were examined for morphological 
signs up to 3 weeks aer reaching conuence. In contrast, aer 
22 days incubation in an adipogenic cocktail, we observed substan-
tial enhancement of this lineage-specic dierentiation by TSHR 
activation, whether assessed morphologically, by semiquanti-
tative ORO staining or qPCR measurement of transcripts for 
LPL (marker of terminal dierentiation) as shown in Figure 2.
We concluded that TSHR activation enhances in vitro-induced 
adipogenesis. e adipogenic cocktail (ADM) used in this study 
contains PPARγ agonist TZD, which is known to stimulate BAT 
formation (40). Consequently, we conducted experiments to 
understand the impact of TSHR activation on BAT formation 
both in basal and induced adipogenesis conditions.
TSHR Activation Enhanced BAT Formation 
of Subcutaneous Precursors
We selected several markers including pre-BAT PRDM16, BAT 
PGC-1α (transcriptional regulator of BAT formation), and UCP1
(terminal BAT marker) (29).
ese were measured in subcutaneous preadipocytes on day 
0 in CM and following in  vitro-induced adipogenesis in TZD-
ADM for 22 days.
On day 0 (basal condition), the cells experiencing TSHR 
activation displayed substantially higher transcript levels of the 
pre-BAT marker, PRDM16, when compared with the control 
population as shown in Figure 3A. However, TSHR activation 
had no signicant eect on expression levels of PGC-1α and 
UCP1 (Figures 3B,C).
By contrast, at day 22 following TZD-ADM induced adipo-
genesis, TSHR activation signicantly increased transcript levels 
of PGC-1α and UCP1 when compared with control cells in ADM 
conditions but lacking TSHR activation (Figures 3B,C).
DISCUSSION
Our study suggests that TSHR activation enhances adipogenesis 
and could contribute to the modulation of fat phenotype.
e ex vivo data demonstrate that in samples of fat from 
TSAB positive GD patients, transcript levels of markers for WAT 
(LEPTIN) and BRITE (CITED1) were signicantly higher than 
in corresponding samples from people with TMNG or controls 
(all TSAB negative). Since all patients were euthyroid at the time 
of surgery, it is reasonable to conclude that the TSAB have a role 
in the observed eect and the presence of TSHR transcripts in all 
samples conrms that this would be plausible.
Having access to samples of neck adipose tissue is fortuitous 
since Cypess and colleagues reported a gradient from the surface 
to the midline of WAT via BRITE to BAT in this region using 
biomarkers, e.g., LEPTIN (WAT), gradient UCP1 expression 
(BRITE to BAT) or ZIC (41, 42). Studies in mice suggest a 
bidirectional interconversion of BRITE and white adipocytes 
(43), with BRITE adipocytes being induced by cold temperature 
into brown fat and conversely returning into white fat at higher 
temperatures. Similarly, Lee et al. found that BRITE fat can be 
transformed into brown or white by adrenergic stimulation 
and high-calorie diet, respectively (44). High thyroid hormone 
levels are known to induce brown fat activity in BAT and BRITE 
fat (3, 4, 45). Of note, the samples from the GD and TMNG 
patients would have previously encountered a period of thyroid 
hormone excess, during the hyperthyroid phase of their condi-
tion but only in GD would there have been simultaneous TSHR 
activation.
We hypothesize that in GD, TSHR activation increases adi-
pogenesis and, combined with excess thyroid hormone, favors 
formation of BAT. is could also explain the heat intolerance 
of GD patients, which is usually attributed to excess thyroid 
hormone increasing metabolic rate. e concept is further sup-
ported by studies in the hyt/hyt mouse, which lacks a functional 
TSHR and deals poorly with low temperature, a characteristic 
which can be overcome by transfecting WT TSHR into the 
animals (22). Proof could be provided by comparing expres-
sion of WAT, BRITE, and BAT markers in adipose tissue from 
TSAB-positive GD patients when hyperthyroid and then when 
euthyroidism is restored; however, patient safety during surgery 
precludes this.
Our in vitro studies conrmed that TSHR activation increases 
adipogenesis in subcutaneous fat, in contrast to orbital fat, in 
which we have previously reported that TSHR activation inhibits 
induced adipogenesis (16). ese eects are the opposite of the 
situation in hyperthyroid GD in which the majority of fat stores 
are depleted, with the exception of orbital fat which expands in 
some patients. Our studies have demonstrated that orbital adipo-
genesis is under diering regulatory mechanisms compared with 
non-orbital fat precursors (46, 47).
We also investigated whether TSHR activation had any eect 
on fat phenotype in vitro, we recognize that there may be some 
overlap in markers for WAT, BAT, pre-BAT, and BRITE but 
have selected the best characterized for each (48). We found 
that subcutaneous precursors, experiencing TSHR activation, 
had signicantly higher transcript levels of the pre-BAT marker, 
PRDM16 in basal conditions. ere were no other indicators of 
spontaneous adipogenesis in these cells. In ADM, TSHR activa-
tion signicantly increased dierentiation and also signicantly 
increased expression levels of BAT markers PGC-1 and UCP1. 
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Our ndings are similar to those of Cypess et al. who induced 
adipogenesis in the presence of Db-cAMP and obtained signi-
cant enhancement of PGC-1α and UCP1 compared with control 
cells in ADM alone (41). In our in vitro model, cells experiencing 
TSHR activation (mutant TSHR) display a twofold to fourfold 
increase in basal cAMP when compared to empty vector control 
cells (16).
e in vitro ndings support our hypothesis that TSHR acti-
vation enhances adipogenesis and favors BAT formation in the 
hyperthyroid state. Our ex vivo ndings imply that enhanced 
adipogenesis persists but the fat phenotype is WAT with some 
features of BRITE rather than BAT. Could this contribute to 
the weight gain experienced in GD following treatment? If 
increased adipogenesis produces BAT, energy can be dissipated 
as heat (as in GD) and weight will be shed. Once the BAT 
phenotype is lost (posttreatment of GD), then the increased 
adipogenesis would lead to WAT accumulation and weight will 
be gained.
Current therapy is based on inhibiting thyroid hormone 
production medically, surgically, or using radioiodine ablation. 
Future strategies aimed at neutralizing TSAB, for example, using 
TSHR antagonist could be more eective in solving weight 
problem.
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FIGURE 3 | Preadipocytes/broblasts from subcutaneous fat (n = 6) expressing activating thyrotropin receptor (TSHR) mutant L629F (TSHR*) and 
equivalent empty vector controls were cultured until conuent (day 0) before changing to differentiation medium for 22 days. Total RNA was isolated 
before or after adipogenesis. PRDM16 (relative expression ratio) (A), PGC-1α (B), and uncoupling protein 1 (UCP1) (C) transcripts were measured by qPCR. Results 
are expressed as comparative qPCR (relative ratio to APRT) of PRDM16 or absolute qPCR (PGC-1α and UCP1) of transcript copy number (TCN) per 1,000 copies 
of housekeeper gene APRT (adenosine phosphoribosyl transferase). Histograms = mean ± SEM of all samples studied (each performed in duplicate). Two-tailed 
t-test or Mann–Whitney test used for statistic analysis (*p < 0.03; **p = 0.01).
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